Covering the Cover Gastroenterology Anson W. Lowe, Richard H. Moseley  Gastroenterology  Volume 149, Issue 2, Pages 263-265 (August 2015) DOI: 10.1053/j.gastro.2015.06.022 Copyright © 2015 AGA Institute Terms and Conditions

Figure 1 Fecal infliximab concentrations up to 14 days after IFX therapy for clinical response at week 2, endoscopic response at week 8 and clinical response at 3 months. 3m, 3 months; CR, clinical response; ER, endoscopic response; IFX, infliximab; NR, nonresponse; w2, week 2; w8, week 8. Gastroenterology 2015 149, 263-265DOI: (10.1053/j.gastro.2015.06.022) Copyright © 2015 AGA Institute Terms and Conditions

Figure 2 Two- and 6-month overall mortality probability according to the joint-effect model combining the Lille model and MELD score. +, hypothetical patient with a MELD score at 21 and a Lille score at 0.45: 2-month mortality rate is 15.3% and 6-month mortality rate is 23.7%. Gastroenterology 2015 149, 263-265DOI: (10.1053/j.gastro.2015.06.022) Copyright © 2015 AGA Institute Terms and Conditions